The ID and password have already been sent to the email address that you provided for your registration.
If you haven't received them yet, then please contact us.
Registration / Technical Issues: Tel: +82-2-373-1005
Email: secretariat@applecongress.org
The ID and Password is valid for 30 days.
Available Login Time: From 08:00AM (GMT+08:00 China), August 11, 2022
August 11, Thursday (GMT+8, China Time)
SESSION 1: PATHOGENESIS
75 min
Chairpersons: Kwang-Hyub Han, Sheng-Long Ye
09:00-09:20
Risk factors and epidemiology
Junqi Niu, Jilin Univ., Jilin
09:20-09:40
Molecular pathogenesis of HCC
Young Nyun Park, Yonsei Univ., Seoul
09:40-10:00
Understanding immunobiology of hepatocellular carcinoma for biomarkers and therapeutic discovery
Valerie Chew, Duke-NUS, Singapore
10:00-10:15
Q&A
10:15-10:30
Break
SESSION 2: BIOMARKERS
100 min
Chairpersons: Irene Ng, Namiki Izumi
10:30-10:50
Molecular detection, disease classification, and diagnosis (HCC, CC)
Michiie Sakamoto, Keio Univ., Tokyo
10:50-11:10
Biomarkers for prognostication
Jooho Lee, CHA Univ., Bundang
11:10-11:30
Molecular biomarkers for systemic therapy
Masafumi Ikeda, National Cancer Center Hospital EAST, Kashiwa
11:30-11:50
Neoadjuvant systemic therapy: avenue to novel biomarker development
Do-Young Kim, Yonsei Univ., Seoul
11:50-12:10
Q&A
12:10-13:10
Break
SESSION 3: TREATMENT
100 min
Chairperson: Chih-Hung Hsu
13:10-13:30
Molecular targeted therapies in HCC / Immunotherapies
Joong-Won Park, National Cancer Center, Goyang
13:30-14:00
Molecular mechanisms of immunotherapies
Ghassan Abou-Alfa, Memorial Sloan Kettering, New York
14:00-14:20
Liver directed therapy (e.g. external beam radiation therapy and trans-arterial chemotherapy)
Jason Chia-Hsien Cheng, National Taiwan Univ., Taipei
14:20-14:50
Q&A
14:50-15:05
Break
SESSION 4: RESEARCH AND CLINICAL TRIAL METHODOLOGY
75 min
Chairpersons: Chiun Hsu, Joong-Won Park
15:05-15:25
Tissue biopsy: the role in HCC management
Haeryoung Kim, Seoul National Univ., Seoul
15:25-15:45
Trial design and endpoints in HCC: A surgeon's point of view
Pierce Chow, National Cancer Centre Singapore, Singapore
15:45-16:05
Trial design and endpoints in HCC: An oncologist's point of view
Thomas Yau, The Univ. of Hong Kong, Hong Kong
16:05-16:20
Q&A
Closing Remarks
16:20-16:25
Closing Remark
Jinsil Seong, Yonsei Univ., Seoul
Satellite Symposium - Eisai
16:25-17:15
